0000899243-21-025983.txt : 20210625
0000899243-21-025983.hdr.sgml : 20210625
20210625170121
ACCESSION NUMBER: 0000899243-21-025983
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210412
FILED AS OF DATE: 20210625
DATE AS OF CHANGE: 20210625
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Tamboli Ajim
CENTRAL INDEX KEY: 0001855684
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40522
FILM NUMBER: 211048815
MAIL ADDRESS:
STREET 1: MONTE ROSA THERAPEUTICS, INC.
STREET 2: 40 GUEST STREET
CITY: BOSTON
STATE: MA
ZIP: 02135
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Monte Rosa Therapeutics, Inc.
CENTRAL INDEX KEY: 0001826457
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 645 SUMMER STREET
STREET 2: SUITE 102
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 617-949-2643
MAIL ADDRESS:
STREET 1: 645 SUMMER STREET
STREET 2: SUITE 102
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-04-12
0
0001826457
Monte Rosa Therapeutics, Inc.
GLUE
0001855684
Tamboli Ajim
MONTE ROSA THERAPEUTICS, INC.
645 SUMMER STREET, SUITE 102
BOSTON
MA
02210
0
1
0
0
Chief Financial Officer
Stock Option (Right to Buy)
6.14
2021-04-12
4
A
0
100938
0.00
A
2031-04-12
Common Stock
100938
100938
D
Stock Option (Right to Buy)
19.00
2021-06-23
4
A
0
56649
0.00
A
2031-06-22
Common Stock
56649
56649
D
On June 17, 2021, the Issuer completed a one-for-3.5305 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split.
This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The securities covered by such transaction were previously included on the Reporting Person's Form 3.
25% of this option shall vest and become exercisable on April 9, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.
25% of this option shall vest and become exercisable on May 28, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.
/s/ Ajim Tamboli
2021-06-25